NCT07560280

Brief Summary

"Cerebral Tinnitus," also known as "cranial tinnitus," refers to the patient-reported perception of intracranial sounds. It often presents as "Cerebral Tinnitus Syndrome," which includes symptoms such as tinnitus with hearing loss, headaches, a heavy head sensation, blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, and depression. Due to limited awareness of cerebral tinnitus, patients frequently seek treatment across multiple facilities without success, severely impacting their and their families' lives and work. Xunming Ji and colleagues have pointed out that cerebral tinnitus results from stenosis of the cerebral or internal jugular veins (IJVS), which impairs cerebral venous outflow and the clearance of metabolic "waste," leading to chronic metabolic damage to brain cells. Currently, studies on the diagnosis and treatment of IJVS-induced cerebral tinnitus, both domestically and internationally, are primarily case reports, lacking systematic evaluation, diagnostic, and treatment standards, which significantly impacts patient outcomes. Our project team is the first to establish evaluation criteria, diagnostic standards, surgical indications, and surgical standards for "Cerebral Tinnitus Syndrome." In preliminary work, we performed internal jugular vein (IJV) decompression on 32 cerebral tinnitus patients, resulting in an IJV morphological improvement rate of 84.3%, a blood flow improvement rate of 75.0%, and a cerebral tinnitus syndrome improvement rate of 62.5%. To date, we have completed 88 IJV decompression surgeries, making ours the largest clinical center for such cases worldwide. We continue to refine these standards, notably introducing new intraoperative standards for IJV "release" and "high perfusion,". To validate and further study these standards, this project plans to perform IJV decompression surgery on 107 cerebral tinnitus patients affected by IJVS. We aim to establish a cerebral tinnitus database and develop a cerebral tinnitus evaluation scale to standardize evaluation criteria, diagnostic standards, surgical indications, and surgical standards, ultimately advancing clinical diagnosis and treatment of Cerebral Tinnitus Syndrome

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
369

participants targeted

Target at P75+ for not_applicable

Timeline
57mo left

Started May 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
May 2025Dec 2030

Study Start

First participant enrolled

May 7, 2025

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 1, 2026

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2030

Last Updated

May 1, 2026

Status Verified

May 1, 2025

Enrollment Period

4.7 years

First QC Date

April 24, 2026

Last Update Submit

April 24, 2026

Conditions

Keywords

Non-randomized Controlled Clinical Trial

Outcome Measures

Primary Outcomes (1)

  • Cerebral tinnitus improvement rate at 3 months postoperatively

    Assessed by VAS score (0-10). Improvement defined as: Marked improvement: ≥30% reduction in VAS Mild improvement: 10%-30% reduction No obvious change: 0%-10% reduction Aggravation: increased VAS

    3 months postoperatively

Secondary Outcomes (5)

  • Cerebral tinnitus improvement rate at 12 months postoperatively

    12 months postoperatively

  • Improvement rate of other clinical symptoms at 3 and 12 months postoperatively

    3 and 12 months postoperatively

  • Morphological improvement of the internal jugular vein (IJV) postoperatively

    3 and 12 months postoperatively

  • Blood flow recovery of IJV postoperatively

    3 and 12 months postoperatively

  • Safety outcomes

    3 and 12 months postoperatively

Study Arms (1)

Surgical Intervention Group

EXPERIMENTAL

Internal Jugular Vein Decompression is a surgical procedure designed to relieve stenosis or external compression of the internal jugular vein, restore normal cerebral venous outflow, and alleviate symptoms related to chronic venous congestion such as pulsatile tinnitus (tinnitus cerebri), positional headache, and visual disturbances.It can be performed via open surgical decompression (releasing surrounding soft tissue/bony compression) or endovascular intervention (balloon angioplasty/stenting) to treat significant jugular vein stenosis refractory to medical management.

Procedure: Atlas Transverse Process Mastoidectomy with Lysis and Perfusion

Interventions

This surgical procedure is performed with the patient in the lateral decubitus position (affected side up), under electrophysiological monitoring of the sternocleidomastoid and trapezius muscles. A 3-4 cm straight incision is made below the mastoid tip, and the atlas transverse process is exposed via careful dissection along the anterior border of the sternocleidomastoid muscle while preserving the cervical branch of the facial nerve. Under endoscopy and microscopy, the anterolateral portion of the transverse process is thoroughly drilled using diamond burrs (4 mm and 2 mm) according to preoperative CTV measurements. After bone resection, the carotid sheath is opened to expose the internal jugular vein (IJV), and perivascular soft tissues are fully released over a width of more than 2 cm to decompress the entire J3 segment of the IJV. Subsequently, the systolic blood pressure is elevated by at least 20% above baseline and maintained for 30 minutes to achieve IJV hyperperfusion and prom

Surgical Intervention Group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 75 years, with no gender restriction.
  • Presence of one or more symptoms associated with "Cerebral Tinnitus Syndrome," with a duration of at least 3 months.
  • Following a detailed medical history and comprehensive physical examination, other known causes of cerebral tinnitus are preliminarily excluded, with suspected internal jugular vein stenosis (IJVS) as the cause.
  • Imaging studies (e.g., jugular ultrasound, cervical venous CT venography (CTV)) show significant stenosis in the internal jugular vein (stenosis degree ≥50%).
  • The patient has provided informed consent and voluntarily agrees to participate in the study, with a signed informed consent form.

You may not qualify if:

  • Patients with a history of cranial surgery or diagnosed intracranial space-occupying lesions.
  • Patients with severe cardiac, hepatic, or renal insufficiency, or other systemic diseases.
  • Patients who have undergone any surgical or interventional procedures affecting jugular venous flow within the last 6 months.
  • Patients with a history of psychiatric disorders or cognitive impairment who cannot complete study evaluations.
  • Pregnant or breastfeeding women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100038, China

RECRUITING

Related Publications (1)

  • Li M, Sun Y, Chan CC, Fan C, Ji X, Meng R. Internal jugular vein stenosis associated with elongated styloid process: five case reports and literature review. BMC Neurol. 2019 Jun 4;19(1):112. doi: 10.1186/s12883-019-1344-0.

    PMID: 31164090BACKGROUND

MeSH Terms

Interventions

Perfusion

Intervention Hierarchy (Ancestors)

Investigative Techniques

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2026

First Posted

May 1, 2026

Study Start

May 7, 2025

Primary Completion (Estimated)

December 30, 2029

Study Completion (Estimated)

December 30, 2030

Last Updated

May 1, 2026

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

Baseline demographic data (age, gender, body mass index, medical history). Preoperative and postoperative VAS scores for tinnitus cerebri and other clinical symptoms at 3 and 12 months. Imaging measurements: IJV diameter on CTV at the decompressed segment pre- and postoperatively. Hemodynamic data: blood flow velocity of the IJV J3 segment measured by Doppler ultrasound. Safety data: occurrence, time, and severity of adverse events and serious adverse events. Data will be shared after de-identification, without exposing participant privacy or protected health information.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
The IPD and related supporting information will be made available \*\*starting from the date of study completion\*\*, and will remain accessible for \*\*5 years after the end of the study\*\*.
Access Criteria
Clinical Study Report (CSR)
More information

Locations